182 related articles for article (PubMed ID: 35790845)
21. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
Xie C; Drenberg C; Edwards H; Caldwell JT; Chen W; Inaba H; Xu X; Buck SA; Taub JW; Baker SD; Ge Y
PLoS One; 2013; 8(11):e79106. PubMed ID: 24244429
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.
Ma J; Li X; Su Y; Zhao J; Luedtke DA; Epshteyn V; Edwards H; Wang G; Wang Z; Chu R; Taub JW; Lin H; Wang Y; Ge Y
Sci Rep; 2017 Feb; 7():41950. PubMed ID: 28176818
[TBL] [Abstract][Full Text] [Related]
23. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.
Qi W; Xie C; Li C; Caldwell JT; Edwards H; Taub JW; Wang Y; Lin H; Ge Y
J Hematol Oncol; 2014 Aug; 7():53. PubMed ID: 25084614
[TBL] [Abstract][Full Text] [Related]
24. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
[TBL] [Abstract][Full Text] [Related]
25. Role of Chk1 and Chk2 in Ara-C-induced differentiation of human leukemia K562 cells.
Takagaki K; Katsuma S; Kaminishi Y; Horio T; Tanaka T; Ohgi T; Yano J
Genes Cells; 2005 Feb; 10(2):97-106. PubMed ID: 15676021
[TBL] [Abstract][Full Text] [Related]
26. ATP depletion triggers acute myeloid leukemia differentiation through an ATR/Chk1 protein-dependent and p53 protein-independent pathway.
Chakrabarti A; Gupta K; Sharma JP; Yang J; Agarwal A; Glick A; Zhang Y; Agarwal M; Agarwal MK; Wald DN
J Biol Chem; 2012 Jul; 287(28):23635-43. PubMed ID: 22621920
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of pyrimidine biosynthesis by strobilurin derivatives induces differentiation of acute myeloid leukemia cells.
Shen X; Zhang L; Xing S; Zhang XW; Xiong GL; Cong YW; Xiao H; Wang XR; Yu ZY
Leuk Lymphoma; 2022 May; 63(5):1202-1210. PubMed ID: 34877904
[TBL] [Abstract][Full Text] [Related]
28. CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia.
Ding H; Vincelette ND; McGehee CD; Kohorst MA; Koh BD; Venkatachalam A; Meng XW; Schneider PA; Flatten KS; Peterson KL; Correia C; Lee SH; Patnaik M; Webster JA; Ghiaur G; Smith BD; Karp JE; Pratz KW; Li H; Karnitz LM; Kaufmann SH
Cancer Res; 2021 May; 81(10):2666-2678. PubMed ID: 33414171
[TBL] [Abstract][Full Text] [Related]
29. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of mitochondrial complex III or dihydroorotate dehydrogenase (DHODH) triggers formation of poly(A)
Miyake S; Masuda S
RNA Biol; 2022 Jan; 19(1):1244-1255. PubMed ID: 36412986
[TBL] [Abstract][Full Text] [Related]
31. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer.
Mullen NJ; Thakur R; Shukla SK; Chaika NV; Kollala SS; Wang D; He C; Fujii Y; Sharma S; Mulder SE; Sykes DB; Singh PK
Cancer Lett; 2023 Jan; 552():215981. PubMed ID: 36341997
[TBL] [Abstract][Full Text] [Related]
32. Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia.
Lewis TA; Sykes DB; Law JM; Muñoz B; Rustiguel JK; Nonato MC; Scadden DT; Schreiber SL
ACS Med Chem Lett; 2016 Dec; 7(12):1112-1117. PubMed ID: 27994748
[TBL] [Abstract][Full Text] [Related]
33. ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.
Boudny M; Trbusek M
Cancer Treat Rev; 2020 Aug; 88():102026. PubMed ID: 32592909
[TBL] [Abstract][Full Text] [Related]
34. A Combined Chemical, Computational, and In Vitro Approach Identifies SBL-105 as Novel DHODH Inhibitor in Acute Myeloid Leukemia Cells.
Kamli H; Zaman GS; Shaikh A; Mobarki AA; Rajagopalan P
Oncol Res; 2022 Jan; 28(9):899-911. PubMed ID: 34353411
[TBL] [Abstract][Full Text] [Related]
35. Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.
Becker JS; Fathi AT
Curr Cancer Drug Targets; 2020; 20(7):490-500. PubMed ID: 32329690
[TBL] [Abstract][Full Text] [Related]
36. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
[TBL] [Abstract][Full Text] [Related]
37. [Novel therapies for acute myeloid leukemia based on genomic aberrations].
Umezawa Y; Kawamata N
Rinsho Ketsueki; 2019; 60(6):594-599. PubMed ID: 31281150
[TBL] [Abstract][Full Text] [Related]
38. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.
Brendel C; Teichler S; Millahn A; Stiewe T; Krause M; Stabla K; Ross P; Huynh M; Illmer T; Mernberger M; Barckhausen C; Neubauer A
PLoS One; 2015; 10(4):e0123181. PubMed ID: 25901794
[TBL] [Abstract][Full Text] [Related]
40. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]